A recent study by the National Business Group on Health (NBGH) found that about 39 percent of employers are mulling how to tackle high-cost claims as 2020 nears, according to a HealthPayerIntelligence report.
The study included input from 147 large employers responsible for some 15.6 million workers and their dependents, per the report. Fifty-four percent of the respondents were Fortune 500 companies.
“Employers are very concerned about how to finance the high cost of new million-dollar drug therapies,” NBGH CEO and President Brian Marcotte said. “Some of these therapies will cost more than what an employee will earn in a lifetime.”
To read the full report on HealthPayerIntelligence, click here.